Several Prostate Cancer Drug Candidates Heading Into Home Stretch
This article was originally published in Pharmaceutical Approvals Monthly
In the next year or so, the race to develop new drug therapies for aggressive end-stage prostate cancer could heat up considerably, with several late-stage therapies due to report data in 2009 and early 2010.
You may also be interested in...
Technology offers more rapid feedback on metastatic cancer progression than imaging or tumor-localized biomarker tests, clinic says.
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.